Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Immunonutrition for Prehabilitation of Patients With Colorectal Cancer Before Surgery (IMNUTPREH-CRC)

Study of Nutritional Management for Prehabilitation: Surgical and Nutritional Outcomes in Patients With Colorectal Cancer Treated With Oral Nutritional Supplements With and Without Immunonutrition.

Perioperative immunonutrition has been proposed as a strategy to modulate the inflammatory response and improve outcomes after colorectal surgery. However, clinical evidence is heterogeneous, and there are few studies that integrate morbidity outcomes with objective measures of body composition using computed tomography (CT). The objective was to compare immunonutrition versus standard enteral supplementation in surgically treated patients with colorectal cancer, evaluating postoperative complications and changes in body composition.

This study was designed as a 1:1 randomized, open-label, two-arm clinical trial: CONTROL group (standard nutritional oral supplements) and IMMUNONUTRITION (immunonutrition oral supplements). Patients were prescribed these daily oral nutritional supplements at least five days before surgery.

PRIMARY OUTCOME: Post-surgical complications were classified as general and post-surgical; severity was assessed using the Clavien-Dindo classification and global burden with the Comprehensive Complication Index (CCI).

SECONDARY OUTCOMES: Body composition was quantified using preoperative and first postoperative CT scans, analyzing skeletal muscle mass index (SMMI), psoas area, periabdominal musculature, and fat compartments.

Intragroup changes and the percentage of change between groups were compared. An exploratory analysis was performed in patients with sarcopenia defined by SMMI cut-off points.

HYPOTHESIS:

It is expected that preoperative immunotherapy may result in less post-surgical complications and better body composition.

Studieöversikt

Studietyp

Interventionell

Inskrivning (Faktisk)

56

Fas

  • Inte tillämpbar

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

    • Madrid
      • Madrid, Madrid, Spanien, 28034
        • Hospital Universitario Ramon y Cajal

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

  • Vuxen
  • Äldre vuxen

Tar emot friska volontärer

Nej

Beskrivning

Inclusion Criteria:

  • Patients eligible for colorectal cancer surgery

Exclusion Criteria:

  • Non-surgical colorectal cancer
  • End-stage liver o kidney disease
  • Emergency surgery
  • Previous nutritional supplements
  • Hypersensitivity to arginine, omega-3, or nucleotides
  • Inability for oral nutrition (dysphagia, esophageal/pyloric stenosis)
  • HIV infection
  • Pregnancy
  • Intestinal obstruction
  • Active uncontrolled infection
  • Dementia, advanced degenerative neurological disease.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Aktiv komparator: Control
Standard oral nutritional supplements
Oral nutritional supplement with high protein content but not enriched with arginine or any other component of immunonutrition
Experimentell: Immunonutrition
Oral nutritional supplements with immunonutrition
Oral nutritional supplements with immunonutrition (enriched with arginine, nucleotides, vitamin D and omega-3-fatty acid)

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Post-surgical complications
Tidsram: From surgery until 90 days post-hospital discharge
Complications were classified as general and post-surgical; severity was assessed using the Clavien-Dindo classification and global burden with the Comprehensive Complication Index (CCI).
From surgery until 90 days post-hospital discharge

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Weight (Kg)
Tidsram: From preoperative evaluation until 90 days after hospital discharge
Weight of the patient at each visit
From preoperative evaluation until 90 days after hospital discharge
Height (cm)
Tidsram: From preoperative evaluation until 90 days after hospital discharge
Height of the patient at each visit
From preoperative evaluation until 90 days after hospital discharge
BMI (Kg/m2)
Tidsram: From preoperative evaluation until 90 days after hospital discharge
Body mass index of the patients calculated using weight and height
From preoperative evaluation until 90 days after hospital discharge
Weight loss (%)
Tidsram: From preoperative evaluation until 90 days after hospital discharge
Percentage of weight loss from the preoperative baseline weight of the patient
From preoperative evaluation until 90 days after hospital discharge
MUST (malnutrition universal screening tool) score.
Tidsram: From preoperative evaluation until 90 days after hospital discharge
Nutritional assessment by anthropometric methods including weight, weight loss, height, and body mass index, are used to give the MUST (malnutrition universal screening tool) score.
From preoperative evaluation until 90 days after hospital discharge
Muscle mass - SMMI (cm2/m2)
Tidsram: From preoperative evaluation until 90 days adter surgery
Body composition was quantified using preoperative and first postoperative CT scans, analyzing skeletal muscle mass index (SMMI), psoas area, periabdominal musculature, and fat compartments.
From preoperative evaluation until 90 days adter surgery
Psoas muscle index (cm2/m2)
Tidsram: From preoperative evaluation until 90 days after hospital discharge
Body composition was quantified using preoperative and first postoperative CT scans, analyzing skeletal muscle mass index (SMMI), psoas area and index, periabdominal musculature, and fat compartments.
From preoperative evaluation until 90 days after hospital discharge
Subcutaneous fat tissue (cm2)
Tidsram: From preoperative evaluation until 90 days after hospital discharge
Body composition was quantified using preoperative and first postoperative CT scans, analyzing skeletal muscle mass index (SMMI), psoas area, periabdominal musculature, and fat compartments.
From preoperative evaluation until 90 days after hospital discharge
Visceral fat tissue (cm2)
Tidsram: From preoperative evaluation until 90 days after hospital discharge
Body composition was quantified using preoperative and first postoperative CT scans, analyzing skeletal muscle mass index (SMMI), psoas area, periabdominal musculature, and fat compartments.
From preoperative evaluation until 90 days after hospital discharge

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

1 januari 2024

Primärt slutförande (Faktisk)

31 december 2025

Avslutad studie (Faktisk)

31 mars 2026

Studieregistreringsdatum

Först inskickad

10 juni 2026

Först inskickad som uppfyllde QC-kriterierna

16 juni 2026

Första postat (Faktisk)

17 juni 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

17 juni 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

16 juni 2026

Senast verifierad

1 juni 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

IPD-planbeskrivning

The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy/ethical restrictions, as they contain information that could compromise the privacy of research participants.

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera